SNY vs NVO

For growth investors, Novo Nordisk A/S (NVO) is the stronger pick with 6.

4% revenue growth year-over-year, versus 5. 5% for Sanofi (SNY). Novo Nordisk A/S (NVO) offers the better valuation at 12. 7x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

7x versus Sanofi at 18. 4x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 1x.

Over the past 5 years, Novo Nordisk A/S (NVO) delivered a total return of +39.

0%, compared to +5. 3% for Sanofi (SNY). Over 10 years, the gap is even starker: NVO returned +105. 1% versus SNY's +60. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.

51β versus Novo Nordisk A/S's 1. 56β — meaning NVO is approximately 203% more volatile than SNY relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 67% for Novo Nordisk A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novo Nordisk A/S (NVO) is pulling ahead at 6.

4% versus 5. 5% for Sanofi (SNY). On earnings-per-share growth, the picture is similar: Novo Nordisk A/S grew EPS 1. 8% year-over-year, compared to -7. 3% for Sanofi. Over a 3-year CAGR, NVO leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus 16. 7% for Sanofi — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus 13. 6% for SNY. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2.

1x forward P/E versus 10. 4x for Sanofi — 8. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 14. 2% to $50. 00.

All stocks in this comparison pay dividends.

Sanofi (SNY) offers the highest yield at 5. 0%, versus 4. 0% for Novo Nordisk A/S (NVO).

For long-horizon retirement investors, Sanofi (SNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51), 5. 0% yield). Novo Nordisk A/S (NVO) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SNY: +60. 6%, NVO: +105. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNY is a mid-cap income-oriented stock; NVO is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.